Cardiac disease is a group of disorders of blood vessels and heart. Congenital heart defects, coronary artery disease and heart rhythm problems are some of the major cardiac diseases. Most common cause of heart disease is narrowing or blockage of blood vessels and coronary artery i.e. ischemic heart disease. Cardiac disease is mainly caused due to high cholesterol, smoking and high blood pressure. In addition, several other diseases such as, diabetes and obesity, and lifestyle changes such as poor nutrition, excessive alcohol and physical inactivity causes higher risk of cardiac diseases. In the U.S. heart disease is the leading cause of death in men and women. According to Centers for Disease Control and Prevention in 2010, in the U.S. approximately 600,000 people die due to heart disease. Prevention or control of heart disease is essential. Prevention from heart disease can be done by, controlling high blood pressure, lifestyle changes, lowering cholesterol, exercising and maintaining health weight. Heart disease treatment varies by condition. Cardiovascular implants have unique blood biocompatibility property, to ensure that the device is not rejected due to adverse thrombogenic or hemodynamic blood responses. There are various implantable cardiac devices such as cardiovascular stent, left ventricular assisted device, pacemakers, artificial hearts, defibrillators and vascular grafts. Pacemakers help in controlling the abnormal heart rhythm. Similarly, implantable defibrillator prevents cardiac arrest. Cardiac implant is composed of polymeric material such as hydrolytically degradable polyesters.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/3462
North America dominates the global market for cardiac bio-implant devices due to large number of aging population and lifestyle associated diseases. Asia is expected to show high growth rates in the next five years in the global cardiac bio-implant devices market. China and India are expected to be the fastest growing cardiac bio-implant devices markets in Asia-Pacific region. Some of the key driving forces for cardiac bio-implant devices market in emerging countries are large pool of patients, increase government funding and increasing healthcare expenditure.
In recent times there is increased use of cardiac bio-implant devices due to rise in aging population. Changing lifestyle leading to increase in cardiovascular diseases, improvement of healthcare infrastructure in developing countries and product innovation in implantable cardiac devices are some of the key factors driving the growth for the global cardiac bio-implant devices market. In addition, increasing healthcare awareness is also fuelling the growth of the global cardiac bio-implant devices market. However, limited reimbursement issues and high cost of cardiac bio-implants are some of the major factors restraining the growth for the global cardiac bio-implant devices market.
Request Customization of this Report @ https://www.persistencemarketresearch.com/request-customization/3462
Developing healthcare sector and advancement in infrastructure would lead to growth in cardiac bio-implant devices market in Asia. In addition, increasing preference of minimally invasive surgery would develop opportunity for the global cardiac bio-implant devices market. However, risks associated to cardiac implant surgeries, such as infections, and lifestyle limitations would pose challenges for the global cardiac bio-implant market. Some of the major companies operating in the global cardiac bio-implant devices market are Abbott Laboratories, Inc., Edwards Lifesciences Corporation, St. Jude Medical, Inc., Johnson & Johnson, Sorin Group, Medtronic, Inc. and Boston Scientific Corporation.